Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.33 |
| ▸ | BHMT | Q93088 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455952 | 0.98 | MVD (0.38) | MVDGBA1CA14PDK2SLC6A9 | |
| SCHEMBL19865535 | 0.84 | GBA1 (0.35) | GBA1CA14PDK2HDAC6HDAC1 | |
| SCHEMBL7783463 | 0.84 | HDAC6 (0.38) | GBA1CA14PDK2HDAC6HDAC1 | |
| SCHEMBL25479216 | 0.84 | CA14 (0.42) | GBA1CA14PDK2HDAC6HDAC1 | |
| SCHEMBL18257000 | 0.84 | CA14 (0.42) | GBA1CA14PDK2HDAC6HDAC1 | |
| SCHEMBL10260946 | 0.83 | HDAC6 (0.40) | GBA1CA14PDK2HDAC6HDAC1 | |
| SCHEMBL19865534 | 0.82 | CHRNB2 (0.37) | GBA1CA14PDK2HDAC6HDAC1 | |
| SCHEMBL25970378 | 0.82 | CA14 (0.40) | GBA1CA14PDK2HDAC6HDAC1 | |
| SCHEMBL336495 | 0.81 | HDAC6 (0.37) | MVDGBA1CA14PDK2HDAC6 | |
| SCHEMBL13244217 | 0.81 | GBA1 (0.34) | GBA1CA14PDK2HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619037-A1 | SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | Lerchen, Hans-Georg (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-20250032477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2025-01-30 | — | — | US | disclosed |
| EP-4412655-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | Vincerx Pharma GmbH (DE) | 2024-08-14 | — | — | EP | disclosed |
| EP-4412656-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | Vincerx Pharma GmbH (DE) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024105197-A1 | SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | VINCERX PHARMA GMBH (DE) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023057813-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057814-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057812-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057812-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057814-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | PCNA, TOP1, TOP2A | MVD 875/4885GBA1 2302/4885CA14 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.